Table 4.
The diagnosis, treatment, and prognosis of PAS patients.
| No. | Sex/Age | Site | Histopathological diagnosis | Treatments | Clinical outcomes |
|---|---|---|---|---|---|
| 1 | F/39 | PT, RPA, LPA | Intimal sarcoma | PEA and chemotherapy | Alive, followed for 18 months |
| 2 | F/52 | PT, RPA, LPA, PV, RVOT, lung | Undifferentiated pleomorphic sarcoma | PEA and chemotherapy | PAS recurrence two months after PEA |
| 3 | M/54 | PT, LPA | Spindle cell sarcoma | PEA, chemotherapy and targeted therapy | Alive, followed for 10 months |
| 4 | F/53 | RPA, LPA, lung, bone | Spindle cell sarcoma | Chemotherapy, immunotherapy and targeted therapy | Alive, followed for nine months |
| 5 | F/53 | RPA, pleura | Spindle cell sarcoma | Chemotherapy and targeted therapy | Alive, followed for 10 months |
| 6 | F/62 | PT, RPA, LPA | – | Waiting for PEA | Alive, followed for 11 months |
| 7 | M/19 | PT, RPA, LPA, lung | Intimal sarcoma | Chemotherapy | Died after nine months |
| 8 | M/35 | PT, RPA, LPA, RVOT, lung | Intimal sarcoma | PEA | PAS recurrence after three months |
| 9 | M/65 | PT, RPA, LPA, lung, lymph nodes | – | – | Died during EBUS-TBNA |
| 10 | M/53 | PT, RPA | spindle cell sarcoma | Chemotherapy and immunotherapy | PAS recurrence after three months |
| 11 | F/61 | PT, RPA, RVOT | – | – | Died after three months |
| 12 | M/26 | RPA, lung, lymph nodes, bones, muscle | Synovial sarcoma | Chemotherapy | Died after 13 months |
| 13 | F/42 | RPA, lung, lymph nodes, adrenal gland | Intimal sarcoma | Chemotherapy | Alive, followed for five months |
PAS: pulmonary artery sarcoma; PT: pulmonary trunk; RPA: right pulmonary artery; LPA: left pulmonary artery; RVOT: right ventricular outflow tract; PV: pulmonary valve; PEA: pulmonary endarterectomy; EBUS-TBNA: endobronchial ultrasound-guided transbronchial needle aspiration.